Inventiva (IVA) Cash from Financing Activities (2019 - 2022)
Inventiva's (IVA) quarterly Cash from Financing Activities came in at $14.2 million in Q4 2022, up 40038.88% year-on-year from N/an in Q4 2021, and down 2.22% quarter-over-quarter from $14.6 million in Q3 2022.
Inventiva (IVA) Cash from Financing Activities (2019 - 2022) Analysis & Trends
Inventiva's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $14.2 million for Q4 2022.
- On a quarterly basis, Cash from Financing Activities rose 40038.88% year-over-year to $14.2 million in Q4 2022; TTM through Dec 2022 was $28.9 million, a 1.79% decrease from a year earlier, with the FY2025 full-year figure at $280.9 million, up 80.54% from the prior year.
- Cash from Financing Activities declined to $14.2 million in Q4 2022 per IVA's latest filing, from $14.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $29.3 million in Q4 2020 and bottomed at -$132826.5 in Q4 2019.
- The 4-year median for Cash from Financing Activities is $11.0 million (2020), against an average of $9.5 million.
- Across the five-year window, Cash from Financing Activities plunged 100.12% in 2021 and surged 40038.88% in 2022, its largest moves.
- Year by year, Cash from Financing Activities stood at -$132826.5 in 2019, then surged by 22187.97% to $29.3 million in 2020, then tumbled by 99.88% to $35463.1 in 2021, then jumped by 40038.88% to $14.2 million in 2022.
- Per Business Quant, the three latest IVA Cash from Financing Activities figures stand at $14.2 million (Q4 2022), $14.6 million (Q3 2022), and $35463.1 (Q4 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 14.23 Mn |
| Dec 31, 2022 | 14.23 Mn |
| Sep 22, 2022 | 14.56 Mn |
| Sep 22, 2022 | 14.56 Mn |
| Dec 31, 2021 | 35,463.10 |
| Dec 31, 2021 | 35,463.10 |
| Jun 30, 2021 | 56,600.76 |
| Jun 30, 2021 | 56,600.76 |
| Mar 31, 2021 | -19,299.78 |
| Mar 31, 2021 | -19,299.78 |
| Dec 31, 2020 | 29.34 Mn |
| Dec 31, 2020 | 29.34 Mn |
| Jun 30, 2020 | 10.99 Mn |
| Jun 30, 2020 | 10.99 Mn |
| Mar 31, 2020 | 16.15 Mn |
| Mar 31, 2020 | 16.15 Mn |
| Dec 31, 2019 | -132,826.52 |
| Dec 31, 2019 | -132,826.52 |